MDR Rule 14: The Ancillary Test That Forces Class III

Manufacturers routinely under-classify devices with a built-in substance because the substance looks minor: a thin anticoagulant coating, a trace antibiotic in a bone cement, a stabilizing agent in a blood bag. Annex VIII's Rule 14 does not ask how much of the substance is present or how central it looks to the device's marketing story. It asks one question — would this substance, used separately, be considered a medicinal product? — and a yes puts the device in Class III regardless of the answer to every other question a manufacturer might think is relevant.

The test is binary, not proportional

Teams that come from a combination-product background often import an instinct from the Article 117/PMOA world: that classification scales with how much the substance contributes to the product's overall effect. Rule 14 does not work that way. The rule asks whether the integral substance would, on its own, meet the definition of a medicinal product under Directive 2001/83/EC — and if it would, the device is Class III, full stop. A trace coating and a substantial reservoir of the same qualifying substance land in the same class, because the rule is built around what the substance is, not how much of it is present.

Where the ancillary line actually falls

The harder question Rule 14 raises is not whether the substance would qualify as medicinal — that is usually clear — but whether its action is ancillary to the device's own principal action, because a product where the substance's effect is not ancillary but dominant is not a device under Rule 14 at all; it falls to be regulated as a medicinal product instead. MDCG 2022-5 works through this with specific examples:

• Heparin- or antibiotic-coated catheters. The catheter's mechanical function — vascular access, drainage, delivery — is principal; the coating's anticoagulant or antimicrobial effect supports that function without becoming the product's reason for existing.
• Antibiotic-loaded bone cement. The cement's structural and fixation role is principal; the antibiotic's local infection-control effect is ancillary to it.
• Blood bag sets with an anticoagulant agent. Industry guidance treats bags containing substances such as heparin, if used separately, as triggering Rule 14 — though manufacturer and industry bodies have disputed how the test applies to citrate-based anticoagulant formulations specifically, which is a reminder that borderline Rule 14 calls are not always settled by inspection alone.
• The line that removes Rule 14 entirely. Where the substance's action is the product's main effect rather than a supporting one, the product falls outside device regulation and into medicinal-product review — a different regulatory track, not a different device class.

Rule 14 is not a penalty for including too much of a substance. It is a classification that applies the moment the substance would qualify as medicinal at all, and only asks afterward whether its role is ancillary. Why the proportional instinct misreads the rule

Classification decides whether the consultation even starts

Rule 14 is the upstream gate, not the consultation itself. Once a device is classified under Rule 14, the notified body cannot evaluate the integral substance on its own authority — it must route a scientific-opinion request to a national competent authority or, for substances within EMA's exclusive scope or derived from human blood or plasma, to EMA directly, under Annex IX, Section 5.2. That consultation runs on its own statutory clock and can block certificate issuance outright on an unfavorable opinion — but none of that machinery starts until the Rule 14 classification question is answered correctly in the first place. Teams that settle borderline device-versus-medicinal-product status under MDCG 2022-5's mode-of-action test, then separately and explicitly work the Rule 14 ancillary-action analysis, avoid discovering the classification gap only when a notified body sends the file back.

The practical risk runs in both directions. Under-classifying a Rule 14 device as Class IIa or IIb because the substance seems incidental invites a notified body correction mid-review, with the Annex IX consultation added to the critical path late. Assuming every integral substance triggers Rule 14 without testing the ancillary-versus-principal line risks routing a genuinely drug-led product through device conformity assessment when it should be seeking a marketing authorization instead. Our EU MDR & IVDR and drug delivery systems teams run this classification analysis at the design stage, specifically so the Rule 14 question is settled before a notified body's own read of it becomes the first time anyone asked.